Clinica Dkf S.L.
- Address
- Avenida Del Doctor Arce 27, 28002 Madrid, Spain
Clinica Dkf S.L. - Rheumatology and Immunology Research Center
Clinica Dkf S.L. is a specialized clinical research facility focused on advancing treatment options for immune-mediated inflammatory diseases, with particular expertise in rheumatologic conditions. The center demonstrates strong capabilities in conducting complex therapeutic trials for chronic autoimmune disorders affecting the musculoskeletal system.
- Psoriatic arthritis clinical trials evaluating novel biologic therapies
- Comparative efficacy studies of advanced immunomodulatory agents versus placebo and active reference treatments
- Investigation of subcutaneous biologic DMARDs in TNF-alpha inadequate responders
The research center has established protocols for assessing ACR50 response criteria and evaluating both efficacy and safety profiles of investigational biologics such as sonelokimab. With experience managing trials for patients naive to biologic disease-modifying antirheumatic drugs as well as those with inadequate response to anti-TNF-alpha therapy, Clinica Dkf S.L. offers comprehensive research capabilities in the evolving landscape of psoriatic arthritis treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1MoonLake Immunotherapeutics AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1MoonLake Immunotherapeutics AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinica Dkf S.L.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Subcutaneous Sonelokimab Versus Placebo and Risankizumab in Adults with Active Psoriatic Arthritis and Inadequate Response to TNF-α Inhibitors | MoonLake Immunotherapeutics AG | Phase III | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sonelokimab | 2 | Unknown | 2025-03-25 | 2025-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.